Study: CBG Effective at Treating Progression of Glioblastoma

A preliminary CBG study found that the cannabinoid showed effectiveness at impairing the progression of glioblastoma, which is considered the most aggressive of primary brain tumors.

Full story after the jump.

The cannabinoid cannabigerol (CBG) was found by researchers in Slovenia effective at impairing the progression of glioblastoma – which is considered the most aggressive among primary brain tumors – in a cell culture study published this month in the open-source journal Cells. The study was funded by Australian cannabis company MGC Pharmaceuticals and conducted through the University Medical Centre Ljubljana, Department of Neurosurgery.

The overall survival mean following a glioblastoma diagnosis is just 16 months.

The researchers found that CBD and CBG, both alone and in combination, stopped the proliferation of glioblastoma cells, while a combination of CBG and THC “reduced the viability of both types of cells to a similar extent.” Combining CBD with CBG “was more efficient than with THC,” the researchers found, adding that CBG and CBD “inhibited glioblastoma invasion in a similar manner” to the chemotherapeutic drug temozolomide.

“This is the first report to demonstrate that the non-intoxicating cannabinoid CBG alone and in combination with CBD efficiently targets two key elements that otherwise prevent the successful treatment of GB patients with current therapeutics: Firstly, to overcome [Glioblastoma Stem Cells] resistance to cytotoxic agents and to induce apoptosis, and secondly, to inhibit GB cell invasion.” – Cannabigerol is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma, Cells, Feb. 5, 2021

Additionally, the researchers found CBG showed stronger efficacy to inhibit glioblastoma cells than temozolomide, inhibiting 90% of some cell lines, compared to the 50% inhibited by the chemotherapy drug, but cutting the CBG used dropped the efficacy of other cell lines to 50%, while temozolomide was effective by 40% to 60% on the cell line.

The researchers noted that CBG and CBD also increased appetite while preventing some chemotherapy side effects.

Get daily cannabis business news updates. Subscribe

Have an additional perspective to share? Send us a message to let us know, and if your comment is chosen by our editors it could be featured here.

End


Ganjapreneur is made possible by our partners:

Latest Cannabis News

View all news Get email updates

Featured Business Profiles

Create a profile View all categories

From Our Partners